Clinical trial
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage…
NCT00020462 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020462 |
|---|---|
| Title | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma |
| Official title | Active Specific Immunotherapy for Follicular Lymphomas With Liposomes Containing Tumor-Derived Antigen and IL-2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | aldesleukin, autologous tumor cell vaccine |
| Start date | Feb 1, 2001 |
| First posted | Aug 7, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: